MCID: PYD001
MIFTS: 45

Pyoderma Gangrenosum malady

Categories: Rare diseases, Skin diseases, Bone diseases

Aliases & Classifications for Pyoderma Gangrenosum

About this section
Sources:
10Disease Ontology, 45NIH Rare Diseases, 47Novoseek, 12DISEASES, 51Orphanet, 36MeSH, 65UMLS, 27ICD10, 29ICD9CM, 59SNOMED-CT, 28ICD10 via Orphanet, 37MESH via Orphanet, 66UMLS via Orphanet
See all MalaCards sources

Aliases & Descriptions for Pyoderma Gangrenosum:

Name: Pyoderma Gangrenosum 10 45 47 12 51 36 65

Characteristics:

Orphanet epidemiological data:

51
pyoderma gangrenosum:
Age of onset: Adult; Age of death: normal life expectancy

Classifications:



External Ids:

Disease Ontology10 DOID:8553
ICD1027 L88
ICD9CM29 686.01
MeSH36 D017511
SNOMED-CT59 74578003
Orphanet51 48104
ICD10 via Orphanet28 L88
MESH via Orphanet37 D017511
UMLS via Orphanet66 C0085652
UMLS65 C0085652

Summaries for Pyoderma Gangrenosum

About this section
NIH Rare Diseases:45 Pyoderma gangrenosum is a rare, destructive inflammatory skin disease of which a painful nodule or pustule breaks down to form a progressively enlarging ulcer. lesions may occur either in the absence of any apparent underlying disorder or in association with other diseases, such as ulcerative colitis, crohn's disease, polyarthritis (an inflammation of several joints together), gammopathy, and other conditions . pyoderma gangrenosum belongs to a group of skin diseases in which a common cellular denominator is the neutrophil. neutrophils are a type of white blood cell or leukocyte which form an early line of defense against bacterial infections.  each year in the united states, pyoderma gangrenosum occurs in about 1 person per 100.000 people. last updated: 4/26/2011

MalaCards based summary: Pyoderma Gangrenosum is related to ileocolitis and pyogenic granuloma, and has symptoms including skin rash, pulmonary infiltrates and myositis. An important gene associated with Pyoderma Gangrenosum is PSTPIP1 (Proline-Serine-Threonine Phosphatase Interacting Protein 1), and among its related pathways are Transcription_NF-kB signaling pathway and Monoamine Transport. The drugs sulfapyridine pwdr and clofazimine have been mentioned in the context of this disorder. Affiliated tissues include neutrophil, skin and bone, and related mouse phenotypes are hematopoietic system and immune system.

Wikipedia:68 Pyoderma gangrenosum is a condition that causes tissue to become necrotic, causing deep ulcers that... more...

Related Diseases for Pyoderma Gangrenosum

About this section

Diseases related to Pyoderma Gangrenosum via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50)    (show all 484)
idRelated DiseaseScoreTop Affiliating Genes
1ileocolitis31.3NOD2, TNF
2pyogenic granuloma30.6IL1R1, PSTPIP1
3nasopharyngitis30.3IFNA2, IL1R1
4muckle-wells syndrome29.8IL1R1, MEFV, NLRP3
5pyogenic sterile arthritis, pyoderma gangrenosum, and acne12.7
6pyogenic arthritis, pyoderma gangrenosum and acne12.7
7pyoderma gangrenosum-acne-suppurative hidradenitis syndrome12.6
8polydactyly, postaxial, types a1 and b11.6
9crohn's disease11.0
10pyoderma10.6
11leukemia10.6
12arthritis10.5
13thyroiditis10.5
14prostatitis10.5
15endotheliitis10.5
16cervicitis10.4
17pancreatitis10.4
18breast cancer10.4
19melanoma10.4
20neuronitis10.4
21occipital lobe neoplasm10.4PSTPIP1, TNF
22obesity10.3
23chronic lymphocytic leukemia10.3
24hepatitis10.3
25lymphoma10.3
26adenocarcinoma10.3
27meningitis10.3
28precursor b lymphoblastic lymphoma/leukemia10.3IL1R1, TNF
29turner syndrome10.3IL1R1, TNF
30kernicterus due to isoimmunization10.3IFNA2, TNF
31schizophrenia10.3
32rheumatoid arthritis10.3
33myocardial infarction10.3
34lung cancer10.3
35hiv-110.3
36renal cell carcinoma10.3
37acute myocardial infarction10.3
38gastric cancer10.3
39liver disease10.3
40constrictive pericarditis10.3
41pericarditis10.3
42ovarian cancer10.3
43retinitis10.3
44mediastinitis10.3
45pustulosis of palm and sole10.3NOD2, TNF
46gastroduodenal crohn's disease10.3NOD2, TNF
47hidradenitis10.2NOD2, TNF
48capillary lymphangioma10.2NOD2, TNF
49trichostrongyloidiasis10.2IFNA2, TNF
50cryptomicrotia brachydactyly syndrome10.2IL1R1, NLRP3

Graphical network of the top 20 diseases related to Pyoderma Gangrenosum:



Diseases related to pyoderma gangrenosum

Symptoms for Pyoderma Gangrenosum

About this section

Symptoms:

 51 (show all 8)
  • chronic skin infection/ulcerations/ulcers/cancrum
  • cutaneous rash
  • lung/pulmonary infiltrates
  • myositis
  • vesicles/bullous/exsudative lesions/bullous/cutaneous/mucosal detachment
  • dermal/subcutaneous infiltration/induration
  • erythema/erythematous lesions/erythroderma/polymorphous erythema
  • subcutaneous nodules/lipomas/tumefaction/swelling

HPO human phenotypes related to Pyoderma Gangrenosum:

id Description Frequency HPO Source Accession
1 skin rash hallmark (90%) HP:0000988
2 pulmonary infiltrates hallmark (90%) HP:0002113
3 myositis hallmark (90%) HP:0100614
4 skin ulcer hallmark (90%) HP:0200042
5 abnormal blistering of the skin typical (50%) HP:0008066

Drugs & Therapeutics for Pyoderma Gangrenosum

About this section

Drugs for Pyoderma Gangrenosum (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show all 15)
idNameStatusPhaseClinical TrialsCas NumberPubChem Id
1
Minocyclineapproved, investigationalPhase 317310118-90-85281021
Synonyms:
(2Z,4S,4aS,5aR,12aS)-2-[amino(hydroxy)methylidene]-4,7-bis(dimethylamino)-10,11,12a-trihydroxy-4a,5,5a,6-tetrahydro-4H-tetracene-1,3,12-trione
(4S,4AS,5AR,12AS)-4,7-BIS(DIMETHYLAMINO)-3,10,12,12A-TETRAHYDROXY-1,11-DIOXO-1,4,4A,5,5A,6,11,12A-OCTAHYDROTETRACENE-2-CARBOXAMIDE
(4S,4AS,5ar,12as)-4,7-bis(dimethylamino)-3,10,12,12a-tetrahydroxy-1,11-dioxo-1,4,4a,5,5a,6,11,12a-octahydrotetracene-2-carboxamide
10118-90-8
13614-98-7 (mono-hydrochloride)
4,7-Bis(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,10,12,12a-tetrahydroxy-1,11-dioxo-2-naphthacenecarboxamide
4708-96-7
7-Dimethylamino-6-demethyl-6-deoxytetracycline
AC1NQXWM
Arestin
BRN 3077644
Bio-0062
Borymycin
C07225
C23H27N3O7
CHEBI:50694
CHEBI:529981
CHEMBL1434
CHEMBL259172
CID5281021
CL 59806
CRL-1605 & Minocycline
D05045
Dynacin
HMS2090D03
HSDB 3130
LMPK07000002
 
LS-93850
Lactoferrin B & Minocycline
Lactoferrin H & Minocycline
MINO
MIY
Minociclina
Minociclina [INN-Spanish]
Minociclinum
Minocin
Minocin (Hydrochloride)
Minocline
Minocyclin
Minocycline
Minocycline (USAN/INN)
Minocycline Hydrochloride
Minocycline Monohydrochloride
Minocycline [USAN:BAN:INN]
Minocyclinum
Minocyclinum [INN-Latin]
NCGC00178854-01
NSC 141993
NSC141993
Solodyn
UNII-FYY3R43WGO
Vectrin (Hydrochloride)
Ximino
minociclinum
minocycline
nchembio.559-comp1
2Pharmaceutical SolutionsPhase 3, Phase 27004
3Anti-Infective AgentsPhase 317220
4Anti-Bacterial AgentsPhase 39140
5
Tacrolimusapproved, investigationalPhase 21023104987-11-3445643, 439492, 445647
Synonyms:
(-)-FK 506
(3S,4R,5S,8R,9E,12S,14S,15R,16S,18R,19R,26aS)-5,19-dihydroxy-3-{(1E)-1-[(1R,3R,4R)-4-hydroxy-3-methoxycyclohexyl]prop-1-en-2-yl}-14,16-dimethoxy-4,10,12,18-tetramethyl-8-(prop-2-en-1-yl)-5,6,8,11,12,13,14,15,16,17,18,19,24,25,26,26a-hexadecahydro-3H-15,19-epoxypyrido[2,1-c][1,4]oxazacyclotricosine-1,7,20,21(4H,23H)-tetrone
104987-11-3
109581-93-3 (Hydrate)
15,19-epoxy-3H-pyrido[2,1-c][1,4]oxaazacyclotricosine-1,7,20,21(23H)-tetrone,
3S-[3R*[E(1S*,3S*,4S*)],4S*,5R*,8S*,9E,12R*,14R*,15S*,16R*,18S*,19S*,26aR*]]-5,6,8,11,12,13,14,15,16,17,18,19,24,25,26,26a-hexadecahydro-5, 19-dihydroxy-3-[2-(4-hydroxy-3-methoxycyclohexyl)-1-methylethenyl]-14,16-dimethoxy-4,10,12,18-tetramethyl-8-(2-propenyl)-15,19-epoxy-3H-pyrido[2,1-c] [1,4] oxaazacyclotricosine-1,7,20,21(4H,23H)-tetrone
8-DEETHYL-8-[BUT-3-ENYL]-ASCOMYCIN
8-DEETHYL-8-[but-3-enyl]-ascomycin
AC-1182
AC1L1K7H
AC1L97GB
AC1L9IBU
AKOS005145901
Advagraf
Ambap104987-11-3
Ambap5429
BCBcMAP01_000194
BRD-K35452788-001-02-1
BSPBio-001279
BSPBio_001279
Bio-0921
Bio2_000470
Bio2_000950
C01375
C44H69NO10
CCRIS 7124
CHEBI:100924
CHEBI:61049
CHEMBL1200738
CID11158639
CID11556866
CID439492
CID445643
CID5372
CID5472317
CID6426916
CID6436007
CID6473866
CID6536850
CID6610362
CID6912836
CID9832283
CID9853905
CID9918805
CID9940643
CID9963169
CPD-10016
CPD000466356
D08556
DB00864
DivK1c_001040
FK 506
FK-506
FK5
FK506
FR 900506
FR-900506
FR900506
 
FT-0082660
Fk-506
Fujimycin
Graceptor
HMS1362O21
HMS1792O21
HMS1990O21
HMS2051C18
HMS2093M19
HMS503O21
Hecoria
IDI1_001040
IDI1_002225
K506
KBio1_001040
KBio2_000619
KBio2_003187
KBio2_005755
KBio3_001097
KBio3_001098
KBioGR_000619
KBioSS_000619
L 679934
L-679934
LCP-Tacro
LMPK04000003
LS-64247
MLS000759471
MLS001424054
Modigraf
MolPort-003-666-518
NCGC00163470-01
NCGC00163470-02
NCGC00163470-03
NCGC00163470-04
NCGC00179232-01
NChemBio.2007.16-comp1
NINDS_001040
NSC717865
Prograf
Prograf (TN)
Protopic
Protopy
S5003_Selleck
SAM001246677
SMR000466356
Tacarolimus
Tacrolimus
Tacrolimus (INN)
Tacrolimus (Prograf?)
Tacrolimus (anhydrous)
Tacrolimus Hydrate
Tacrolimus anhydrous
Tacrolimus hydrate
Tsukubaenolide
UNII-Y5L2157C4J
nchembio.2007.23-comp2
tacrolimus
tacrolimus hydrate
6Immunologic FactorsPhase 218483
7Antirheumatic AgentsPhase 28496
8Calcineurin InhibitorsPhase 21223
9Immunosuppressive AgentsPhase 210422
10ImmunoglobulinsPhase 24477
11Antibodies, MonoclonalPhase 22413
12AntibodiesPhase 24477
13
Infliximabapproved349170277-31-3
Synonyms:
Ig gamma-1 chain C region
 
Inflectra
Remicade
Remsima
14Dermatologic Agents4555
15Gastrointestinal Agents6401

Interventional clinical trials:

(show all 14)
idNameStatusNCT IDPhase
1Minocycline Therapy for Lung Scarring in Patients With Idiopathic Pulmonary Fibrosis - a Pilot StudyActive, not recruitingNCT00203697Phase 3
2An Efficacy and Safety Study of Gevokizumab in Treating Active Ulcers of Pyoderma GangrenosumTerminatedNCT02326740Phase 3
3An Efficacy and Safety Study of Gevokizumab in Treating Active Ulcers of Pyoderma GangrenosumTerminatedNCT02315417Phase 3
4A 2-Year, Open-Label, Safety Extension Study of Gevokizumab in Subjects With Pyoderma GangrenosumTerminatedNCT02318914Phase 3
5Proof of Concept Study of Gevokizumab in the Treatment of Pyoderma GangrenosumCompletedNCT01882504Phase 2
6Topical Tacrolimus 0.1% Ointment For Treatment Of Cutaneous Crohn's DiseaseCompletedNCT01233570Phase 2
7RA-18C3 Therapy for Subjects With Pyoderma GangrenosumRecruitingNCT01965613Phase 2
8Canakinumab for Pyoderma GangrenosumRecruitingNCT01302795Phase 2
9Single-arm Study to Assess a Potential Effect of Anti-IL-17 (Secukinumab) in the Treatment of Pyoderma GangrenosumNot yet recruitingNCT02733094Phase 1, Phase 2
10Safety and Efficacy Study of Humira in Treatment of Pyoderma GangrenosumWithdrawnNCT00730717Phase 2
11Study to Determine the Safety and Efficacy of Adalimumab in the Treatment of Pyoderma GangrenosumWithdrawnNCT00690846Phase 2
12Open Label Study for Adults With Pyoderma Gangrenosum and Inflammatory Bowel DiseaseCompletedNCT00791557
13Observational Study of the Genetic Architecture of Neutrophil-Mediated Inflammatory Skin DiseasesRecruitingNCT01952275
14Schnitzler Syndrome: Clinical Study, Physiopathological and Search for Genetic FactorsRecruitingNCT00933296

Search NIH Clinical Center for Pyoderma Gangrenosum

Inferred drug relations via UMLS65/NDF-RT43:


Cochrane evidence based reviews: pyoderma gangrenosum

Genetic Tests for Pyoderma Gangrenosum

About this section

Anatomical Context for Pyoderma Gangrenosum

About this section

MalaCards organs/tissues related to Pyoderma Gangrenosum:

33
Neutrophil, Skin, Bone, Lung, T cells, Breast, Heart

Animal Models for Pyoderma Gangrenosum or affiliated genes

About this section

MGI Mouse Phenotypes related to Pyoderma Gangrenosum:

38
idDescriptionMGI Source AccessionScoreTop Affiliating Genes
1MP:00053977.7IL1R1, MEFV, NLRP3, NOD2, PSTPIP1, TNF
2MP:00053876.8IL1R1, MEFV, MMP10, NLRP3, NOD2, PSTPIP1

Publications for Pyoderma Gangrenosum

About this section

Articles related to Pyoderma Gangrenosum:

(show top 50)    (show all 632)
idTitleAuthorsYear
1
Anti-estrogen Resistance in Human Breast Tumors Is Driven by JAG1-NOTCH4-Dependent Cancer Stem Cell Activity. (26387946)
2015
2
HSP90 protects the human T-cell leukemia virus type 1 (HTLV-1) tax oncoprotein from proteasomal degradation to support NF-I_B activation and HTLV-1 replication. (24109220)
2013
3
Congenital pulmonary airway malformation presenting as unilateral cystic lung disease. (24127801)
2013
4
Surgical approach in a patient with multiple symmetrical lipomatosis: case report. (22392254)
2012
5
NOA-05 phase 2 trial of procarbazine and lomustine therapy in gliomatosis cerebri. (21710625)
2011
6
Treatment of acute anterior cruciate ligament tears. (21668053)
2011
7
Recent discovery of widespread Ixodes affinis (Acari: Ixodidae) distribution in North Carolina with implications for Lyme disease studies. (20618664)
2010
8
The longitudinal profile of CSF markers during external lumbar drainage. (19535354)
2009
9
A highly reproducible rotenone model of Parkinson's disease. (19385059)
2009
10
Serum adiponectin, leptin level, and bone mineral density in postmenopausal women]. (19587442)
2009
11
Lopinavir co-induces insulin resistance and ER stress in human adipocytes. (19501568)
2009
12
Comparative assessment of antiinflammatory action of atorvastatin in ischemic heart disease and rheumatoid arthritis]. (18991814)
2008
13
Umbilical venous volume flow in twin-twin transfusion syndrome. (18837441)
2008
14
Tadalafil and fluoxetine in premature ejaculation: prospective, randomized, double-blind, placebo-controlled study. (18362486)
2008
15
Synergistic effect of thermotherapy in combination with chemotherapy on lung tumor A549 cells growth through activation of c-Jun N-terminal kinase and inhibition of heat shock protein70 expression]. (19069644)
2008
16
Immuno stimulating glycophosphosphingolipid antigen from Leishmania donovani is recognized by visceral leishmaniasis patient sera. (18405984)
2008
17
A 3-month course of long-acting repeatable octreotide (sandostatin LAR) improves portal hypertension in patients with cirrhosis: a randomized controlled study. (17488248)
2007
18
Hypermethylation of the Dal-1 gene in lung adenocarcinomas induced by N-nitrosobis(2-hydroxypropyl)amine in rats. (17415786)
2007
19
G1-G2 aggrecan product that can be generated by M-calpain on truncation at Ala709-Ala710 is present abundantly in human articular cartilage. (17261541)
2007
20
Therapeutic efficacy of sulfadoxin/pyrimethamine in the treatment of uncomplicated Plasmodium falciparum malaria in Enseno, Meskan Woreda, Gurage zone, SNNPR, Ethiopia. (17447375)
2006
21
No evidence of an association between tyrosine hydroxylase gene polymorphisms and suicide victims. (17329957)
2006
22
A cohort study of effectiveness of acetylcholinesterase inhibitors in Alzheimer's disease. (15912389)
2005
23
Differences in dental and bone maturation in regions with or without hemihypertrophy in two patients with Russell-Silver syndrome. (16128247)
2005
24
Inverted terminal repeat sequences of adeno-associated virus enhance the antibody and CD8(+) responses to a HIV-1 p55Gag/LAMP DNA vaccine chimera. (15193918)
2004
25
The molecular triad OPG/RANK/RANKL: involvement in the orchestration of pathophysiological bone remodeling. (15561602)
2004
26
Echinococcus granulosus cattle strain identification in an autochthonous case of cystic echinococcosis in central Mexico. (15533292)
2004
27
Disruption of the c-JUN-JNK complex by a cell-permeable peptide containing the c-JUN delta domain induces apoptosis and affects a distinct set of interleukin-1-induced inflammatory genes. (12832416)
2003
28
Recombinant human monoclonal autoantibodies specific for citrulline-containing peptides from phage display libraries derived from patients with rheumatoid arthritis. (12913924)
2003
29
Rehabilitating a patient with bruxism-associated tooth tissue loss: a literature review and case report. (15061339)
2003
30
The first experience with non-operative treatment of hypersplenism in children with portal hypertension. (12469254)
2002
31
A muscular lesion suggestive of focal myositis in a child with Proteus syndrome. (12439276)
2002
32
Targeting c-kit mutations in solid tumors: scientific rationale and novel therapeutic options. (11740803)
2001
33
Prostaglandin E(2)-induced interleukin-6 release by a human airway epithelial cell line. (11133502)
2001
34
GDNF and neurturin are target-derived factors essential for cranial parasympathetic neuron development. (11585803)
2001
35
A common mechanism for recombinant human NGF, BDNF, NT-3, and murine NGF slow unfolding. (10595557)
1999
36
The effect of transient global ischemia on the interaction of Src and Fyn with the N-methyl-D-aspartate receptor and postsynaptic densities: possible involvement of Src homology 2 domains. (10458595)
1999
37
The Strange Stories Test: a replication with high-functioning adults with autism or Asperger syndrome. (10587886)
1999
38
Advanced testicular germ cell tumor in a hemophilic patient with human immunodeficiency virus infection. (9793032)
1998
39
Effect of the endothelin family of peptides on human coronary artery smooth-muscle cell migration. (9595408)
1998
40
Total hip reconstruction in a woman with Cornelia de Lange syndrome: a case report. (9264220)
1997
41
Differential regulation of leukocyte function-associated antigen-1/ intercellular adhesion molecules-1-dependent adhesion and aggregation in HL-60 cells. (8639786)
1996
42
Different target specificities of phospholipid-dependent antibodies. (8952754)
1996
43
Verrucous carcinoma of the larynx. (7816455)
1995
44
Diagnostic approach to and follow-up of difficult cases of AL amyloidosis. (8566880)
1995
45
MR and MR angiography of Sturge-Weber syndrome. (8456722)
1993
46
Simultaneous purification of the neuroproteins synapsin I and synaptophysin. (1522178)
1992
47
Neuroaxonal dystrophy in childhood. Report of two second cousins with Hallerworden-Spatz disease, and a case of Seitelberger's disease. (7158329)
1982
48
Acute obstructive uropathy due to prolapsed ectopic ureterocele. Case report. (5556873)
1971
49
Evaluation of autonomic nervous system response in patients with the dumping syndrome. (13714130)
1960
50
Local tissue reactivity (Shwartzman phenomenon) in the heart and the femoral artery of the rabbit. (20993489)
1946

Variations for Pyoderma Gangrenosum

About this section

Expression for genes affiliated with Pyoderma Gangrenosum

About this section
Search GEO for disease gene expression data for Pyoderma Gangrenosum.

Pathways for genes affiliated with Pyoderma Gangrenosum

About this section

GO Terms for genes affiliated with Pyoderma Gangrenosum

About this section

Biological processes related to Pyoderma Gangrenosum according to GeneCards Suite gene sharing:

(show all 9)
idNameGO IDScoreTop Affiliating Genes
1positive regulation of cysteine-type endopeptidase activity involved in apoptotic processGO:004328010.2NLRP3, TNF
2positive regulation of interleukin-1 beta secretionGO:00507189.7NLRP3, NOD2
3nucleotide-binding domain, leucine rich repeat containing receptor signaling pathwayGO:00358729.6NLRP3, NOD2
4protein oligomerizationGO:00512599.6NLRP3, NOD2
5defense response to bacteriumGO:00427429.3NOD2, TNF
6cell surface receptor signaling pathwayGO:00071669.2IFNA2, IL1R1, TNF
7positive regulation of NF-kappaB transcription factor activityGO:00510928.9NLRP3, NOD2, TNF
8inflammatory responseGO:00069548.6IFNA2, NLRP3, PSTPIP1, TNF
9defense responseGO:00069528.6IFNA2, NLRP3, NOD2, TNF

Sources for Pyoderma Gangrenosum

About this section
2CDC
14ExPASy
15FDA
16FMA
24GTR
25HGMD
26HMDB
27ICD10
28ICD10 via Orphanet
29ICD9CM
30IUPHAR
31KEGG
34MedGen
36MeSH
37MESH via Orphanet
38MGI
41NCI
42NCIt
43NDF-RT
46NINDS
47Novoseek
49OMIM
50OMIM via Orphanet
54PubMed
55QIAGEN
60SNOMED-CT via Orphanet
64Tumor Gene Family of Databases
65UMLS
66UMLS via Orphanet